Key result
Anti-beta 2-GPI and aCL represent distinct autoantibody populations, with only ~23% concordance in positive sera.
Why the study?
It was unclear whether anticardiolipin and anti-beta 2-GPI antibodies represent two distinct populations and whether the beta 2-GPI phospholipid-binding site is crucial for anti-beta 2-GPI reactivity.
Observational (n=62)
Answers are grounded in this paper and cite their sources.
Distinguishing aCL from anti-β2-GPI may refine APS serology; leaves open whether dual testing improves thrombotic risk stratification.
This study has been undertaken to assess whether anticardiolipin and anti-beta 2-GPI are two distinct populations of (auto)antibodies, and to clarify whether the beta 2-GPI region critical for phospholipid binding is also crucial for anti-beta 2-GPI reactivity. Fourteen of the 62 anticardiolipin (aCL) ELISA positive sera (22.6%) were positive for anti-beta 2-GPI by immunoblotting, 42 (67.7%) for aCL using TLC immunostaining. IgG fractions from 5 sera gave the same anticardiolipin reactivity detected by TLC immunostaining in the corresponding sera. All anti-beta 2-GPI-positive sera were reactive with the phenylthiocarbamyl derivative of the protein, indicating that binding of phenylisothiocyanate with lysine residues does not modify the molecule antigenicity. In addition, incubation of IgG fractions with the phospholipid binding site did not modify reactivity with beta 2-GPI. These findings demonstrate that: a) "true" antiphospholipid antibodies are detectable in patients' sera; b) aCL and anti-beta 2-GPI have a different immunological profile; c) the beta 2-GPI phospholipid-binding site is not the region recognized by the antibodies.
No takes yet. Share an insight, caveat, or question.
Sorice et al. (1996) conducted an observational in Anticardiolipin (aCL) ELISA positive sera (n=62). Autoantibody profiling was evaluated on Positivity for anti-beta 2-GPI and aCL. Analysis of 62 anticardiolipin ELISA positive sera showed that 22.6% were positive for anti-beta 2-GPI and 67.7% for aCL, demonstrating they are distinct autoantibody populations.
Synapse has enriched 10 related papers. Consider them for comparative context: